67: stability, therapeutic efficacy, and safety studies in miceCu-Radiolabeling of a multimeric RGD peptide for α: stability, therapeutic efficacy, and safety studies in miceV: stability, therapeutic efficacy, and safety studies in miceβ: stability, therapeutic efficacy, and safety studies in mice3: stability, therapeutic efficacy, and safety studies in mice integrin-targeted radionuclide therapy: stability, therapeutic efficacy, and safety studies in mice

    loading  Checking for direct PDF access through Ovid

Abstract

Objective

Copper-67 (67Cu) is one of the most promising radionuclides for internal radiation therapy. Globally, several projects have recently been initiated for developing innovative approaches for the large-scale production of 67Cu. Encouraged by these, we performed 67Cu-radiolabeling of a tetrameric cyclic Arg–Gly–Asp (cRGD) peptide conjugate, cyclam-RAFT-c(-RGDfK-)4, which selectively targets αVβ3 integrin (αVβ3), the transmembrane receptor involved in tumor invasion, angiogenesis, and metastasis. We also evaluated the therapeutic potential and safety of this radiocompound.

Materials and methods

67Cu, produced through the 64Ni(α, p)67Cu reaction, was used for the radiolabeling of cyclam-RAFT-c(-RGDfK-)4 at 70°C for 10 min. The radiolabeling efficiency and product stability were assessed using reversed-phase high-performance liquid chromatography and/or thin-layer chromatography. Mice with subcutaneous αVβ3-positive U87MG-glioblastoma xenografts received a single intravenous injection of one of the following: 67Cu-cyclam-RAFT-c(-RGDfK-)4 (11.1 MBq), peptide control, or vehicle solution. The tumor volumes were measured, side effects were assessed in terms of body weight, routine hematology, and hepatic and renal functions, and the mouse radiation dosimetry was estimated.

Results

67Cu-cyclam-RAFT-c(-RGDfK-)4 was produced with a radiochemical purity of 97.9±2.4% and a specific activity of 2.7±0.6 MBq/nmol and showed high in-vitro and in-vivo plasma stability. The administration of a single dose of 67Cu-cyclam-RAFT-c(-RGDfK-)4 resulted in significant tumor growth delay in comparison with that observed upon vehicle or peptide control administration, with an estimated tumor-absorbed dose of 0.712 Gy. No significant toxicity was observed in 67Cu-cyclam-RAFT-c(-RGDfK-)4-treated mice.

Conclusion

67Cu-cyclam-RAFT-c(-RGDfK-)4 would be a promising therapeutic agent for αVβ3 integrin-targeted internal radiotherapy.

Related Topics

    loading  Loading Related Articles